All In Biotech

Drug Trial Radar · NCT03694041

Safety, Tolerability, PK and PD of SAD or MAD of APX-115 in Healthy Male Volunteers

Double Blind, Randomized Study Assessing the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses or Multiple Ascending Doses of APX-115 in Healthy Male Volunteers.

Last checked: Nov 20, 2026Latest source record: Mar 11, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

88

Actual

Start

May 28, 2018

Primary completion

Mar 6, 2019

Study completion Mar 6, 2019

Sponsor

Lead sponsor
Aptabio Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety, tolerabilty, pharmacokinetics and pharmacodynamics of single ascending doses and multiple ascending doses of APX-115 in healthy males. This study also aims to evaluate the effect of food consumption on the pharmacokinetics of APX-115 and potential interaction between caffeine and APX-115 in healthy males.

Conditions

  • Healthy
  • Safety

Interventions

  • SAD: APX-115Drug

    Drug: APX-115 SAD APX-115 SAD for 1day

  • SAD: PlaceboDrug

    Drug: Placebo Placebo for 1day

  • MAD: APX-115Drug

    Drug: APX-115 MAD APX-115 MAD repeatedly administered.

  • MAD: PlaceboDrug

    Matching study drug will be repeatedly administered.

  • Food effect: fasted and fedOther

    A single dose of APX-115, selected from the SAD study, will be administered under fasted and fed condition.

  • Metabolic probe with or without APX-115Other

    A metabolic probe will be administered with and without APX-115.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SAD: incidence of treatment emergent adverse eventsTime frame: Up to Day 8
  2. SAD: number of clinically significant abnormal findings from vital signs (blood pressure, pulse)Time frame: Up to Day 8
  3. SAD: number of clinically significant abnormal findings from physical examTime frame: Up to Day 8
  4. SAD: number of clinically significant abnormal findings from electrocardiogramTime frame: Up to Day 8
  5. SAD: number of clinically significant abnormal findings from biological testsTime frame: Up to Day 8
  6. MAD: incidence of treatment emergent adverse eventsTime frame: Up to Day 17
  7. MAD: number of clinically significant abnormal findings from vital signs (blood pressure, pulse)Time frame: Up to Day 17
  8. MAD: number of clinically significant abnormal findings from physical examsTime frame: Up to Day 17
  9. MAD: number of clinically significant abnormal findings from electrocardiogramTime frame: Up to Day 17
  10. Food effect: peak serum concentration (Cmax) of APX-115 under fasting and fed conditionsTime frame: Up to Day 4 post-dose
  11. Food effect: time to reach the Cmax (Tmax) of APX-115 under fasting and fed conditionsTime frame: Up to Day 4 post-dose
  12. Food effect: area under the curve (AUC) of APX-115 under fasting and fed conditionsTime frame: Up to Day 4 post-dose
  13. Food effect: elimination rate constant (Kel) of APX-115 under fasting and fed conditionsTime frame: Up to Day 4 post-dose
  14. Food effect: ratio AUCfed/AUCfastedTime frame: Up to Day 4 post-dose
  15. Drug interaction: peak serum concentration (Cmax) of a metabolic probe or APX-115Time frame: Up to Day 4 post-dose
  16. Drug interaction: Time to reach the Cmax (tmax) of a metabolic probe or APX-115Time frame: Up to Day 4 post-dose
  17. Drug interaction study: Area under the Curve (AUC) of a metabolic probe or APX-115Time frame: Up to Day 4 post-dose
  18. Drug interaction: elimination rate constant (Kel) of a metabolic probe or APX-115Time frame: Up to Day 4 post-dose
  19. Drug interaction: half-life (t1/2) of a metabolic probe or APX-115Time frame: Up to Day 4 post-dose
  20. Drug interaction: volume of distribution (Vd/f) of a metabolic probe or APX-115Time frame: Up to Day 4 post-dose
  21. Drug interaction: clearance of a metabolic probe or APX-115Time frame: Up to Day 4 post-dose
  22. Drug interaction: Incidences of treatment emergent adverse eventsTime frame: Up to Day 4 post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Eurofins Optimed

    Gières, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.